Fidelity is closing its Disruptive Medicine ETF (FMED), and the timing is strange. Trading in the fund ended on Thursday 12 November 2026, and the fund is expected to liquidate on or about Thursday 19 November 2026, tomorrow. Yet FMED was having its best year in a long time. Over the past 12 months the fund returned 21.4%, and $10,000 invested a year ago is worth $12,136 today. The fund is closing anyway, and anyone who still holds shares needs to know what happens next.
The Numbers at a Glance
- The closure: Fidelity announced on 15 October 2026 that it will liquidate five ETFs, including FMED. The last full trading day was 12 November 2026, and liquidation is expected on or about 19 November 2026.
- The 1-year return: FMED’s share price returned 21.4% over the past year through 12 November, according to StockTitan. With dividends reinvested it is the same 21.4%, because the fund paid no dividends in 2025 or 2026.
- The $10,000 math: $10,000 invested a year ago, on 17 November 2025 at $26.98 a share, is worth $12,136 now. $10,000 invested in June 2023 is worth $12,951, up about 30%.
- The 2026 run: FMED gained 21.0% in 2026 through 12 November, its best stretch since launch, with its best month, August 2026, up 13.5%.
- The longer record: the fund’s own shareholder report puts its 5-year average annual return at minus 2.35% and its life-of-fund return at 2.49% a year. $10,000 invested at launch in April 2020 was worth $11,629 by 31 May 2026.
- The size: the fund held about $52 million in assets at the end of October, and about $30 million by its final trading day, after $22.2 million of net outflows in its final days.
- The cost: the expense ratio is 0.50%, or $50 a year on a $10,000 investment.
Fidelity Is Closing Five ETFs, Not Just FMED
Fidelity announced the closures on 15 October 2026. Five funds are being liquidated: the Fidelity Disruptive Finance ETF (FDFF), the Fidelity Disruptive Medicine ETF (FMED), the Fidelity Disruptors ETF (FDIF), the Fidelity Metaverse ETF (FMET) and the Fidelity Real Estate Investment ETF (FPRO). The announcement, published by Fidelity and carried by Nasdaq, says 12 November 2026 was expected to be the last full day of trading for FDFF, FMED, FDIF and FMET on Nasdaq, and for FPRO on Cboe. Shareholders could sell until the market close on 12 November, after which the shares no longer trade. The funds are expected to liquidate on or about 19 November 2026.
Fidelity did not give a reason for the closures in the announcement. The context is size. FMED held about $52 million in assets at the end of October, according to the American Association of Individual Investors, and ETF Database shows $36.79 million of net outflows over the past year. Fidelity’s wider ETF lineup runs to more than 80 ETFs and exchange-traded products with $189 billion in assets under management as of 30 September 2026, so a $50 million fund is a rounding error in that lineup.
What $10,000 in FMED Is Worth Now
The alert that started this story was StockTitan’s calculator page, “If You Invested in Fidelity Disruptive Medicine ETF (FMED)”. Its figures run through 12 November 2026, the final trading day, and they are based on real historical closing prices. Here is what they show.
A $10,000 investment made a year ago, on 17 November 2025, when FMED traded at $26.98 a share, is worth $12,136. That is a 21.4% price return, and the same with dividends reinvested, because FMED paid no dividend in 2025 or 2026. Its last payout was $0.112 a share on 20 December 2024, according to StockAnalysis.
A $10,000 investment made in June 2023 is worth $12,951, a gain of about 30%. StockTitan’s price history starts on 12 June 2023, so it shows no 5-year or 10-year figure for the fund.
The year-by-year record tells the story of a fund that only recently found its footing:
| Year | FMED price return |
|---|---|
| 2023 (12 June to 29 December) | minus 4.2% |
| 2024 | plus 1.8% |
| 2025 | plus 9.7% |
| 2026 (to 12 November) | plus 21.0% |
Other sources line up with those figures. PortfoliosLab put FMED’s 1-year return at 20.68% and its year-to-date return at 21.03% on 17 November, with the fund trading at about $33 a share, roughly 2.4% below its 52-week high of $33.56. StockAnalysis put the 1-year total return at 20.72%. The small differences come from different measurement dates and from price returns versus net asset value returns. The American Association of Individual Investors, using net asset value data as of 31 October 2026, put the 1-year return higher, at 23.5%, and the year-to-date return at 19.8%.
The 2026 run was volatile even while it was strong. FMED’s best single day was 19 August 2026, up 7.0%, and its worst single day was 5 November 2026, down 6.5%, according to PortfoliosLab. The fund’s deepest drop of 2026 was 16.38%, and its worst drawdown since launch was 21.84% in October 2023.
The Longer Record Was Weak
The strong past year hides a poor longer record, and that is the honest context for the closure. Fidelity’s own annual shareholder report, for the year ended 31 May 2026, puts FMED’s average annual total return at 8.04% over one year, minus 2.35% a year over five years, and 2.49% a year since launch. A $10,000 investment made at launch on 16 April 2020 was worth $11,629 by 31 May 2026. The report is published on Fidelity’s institutional site.
The annual figures from the American Association of Individual Investors, based on net asset value, show the same pattern. FMED returned 9.7% in 2025, 2.4% in 2024, 1.4% in 2023, minus 21.7% in 2022 and 11.0% in 2021. The 2022 loss is the scar: $10,000 invested at the start of 2022 was worth about $7,830 by the end of it. The 5-year annualised return of 0.4% a year means $10,000 invested five years ago is worth only about $10,200 today.
Against its benchmarks, FMED beat its own healthcare yardstick but trailed the broad market. Over the year to 31 May 2026, the MSCI All Country World Healthcare Equal Weighted Index returned 3.22%, against FMED’s 8.04%, while the broad MSCI All Country World Index returned 30.64%, according to Fidelity’s report.
What FMED Actually Owned
FMED was an actively managed fund, not an index tracker. It aimed for long-term growth of capital by investing at least 80% of its assets in disruptive medicine companies, firms with new or unconventional ways of doing business that could displace incumbents over time. The theme covered robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, precision medicine, advanced diagnostics and consumer wellness, according to the fund’s strategy description on MutualFunds.com. The fund was managed by Michael Kim since 2020 and Eddie Yoon since 2025, according to the American Association of Individual Investors.
At the final close the fund held 76 securities, with the top 10 making up 32.80% of assets, according to StockAnalysis. The largest positions were:
| Holding | Weight |
|---|---|
| Thermo Fisher Scientific (TMO) | 4.17% |
| Natera (NTRA) | 3.92% |
| Danaher (DHR) | 3.92% |
| 10x Genomics (TXG) | 3.87% |
| LifeStance Health (LFST) | 3.15% |
| argenx (ARGX) | 2.94% |
| Sartorius Stedim Biotech (DIM) | 2.90% |
| Moderna (MRNA) | 2.75% |
| Illumina (ILMN) | 2.72% |
| Revolution Medicines (RVMD) | 2.46% |
That is a concentrated bet on tools, diagnostics and genomics rather than on the big drug makers. The fund was also expensive for what it held, and thinly traded. Its expense ratio of 0.50% works out at $50 a year on a $10,000 investment, and Fidelity’s shareholder report put the actual cost at $52 on a $10,000 investment for the year ended 31 May 2026. Average daily volume was only about 13,500 shares, according to MarketBeat, and just 10,053 shares changed hands on the final trading day.
How FMED Stacked Up Against XLV
The natural comparison is the Health Care Select Sector SPDR Fund (XLV), the big passive healthcare ETF, which charges 0.08% a year against FMED’s 0.50%. Over three years FMED came out ahead on returns, at 17.57% a year against 16.07% for XLV, according to PortfoliosLab. In 2026, though, XLV pulled ahead, up 22.84% year to date against 21.03% for FMED.
Against its own category, FMED was ordinary. The health category average returned 24.1% over the past year against FMED’s 23.5% on a net asset value basis, and 17.8% a year over three years against 17.2% for FMED, according to the American Association of Individual Investors. FMED also carried a rich valuation: ETF Database put its price-to-earnings ratio at 40.50, against a category average of 16.43.
What Happens to Shareholders Now
If you still hold FMED shares, you cannot sell them on an exchange anymore. Trading ended at the close on 12 November 2026, and Fidelity has said there may be no trading market between the final trading day and liquidation. The fund’s portfolio is being positioned into cash, cash equivalents or other liquid assets, and the fund is expected to liquidate on or about 19 November 2026. Shareholders of record should then receive the cash liquidation proceeds, based on the fund’s final net asset value, through their broker.
Three things are worth checking. First, the exact amount and timing will come in the corporate-action notice from your broker, not from the share price, because there is no share price anymore. Second, the liquidation is normally a taxable event, so the proceeds may create a capital gain or loss depending on what you paid, and the tax result depends on your own situation. Third, the other four funds in the same announcement, FDFF, FDIF, FMET and FPRO, follow the same timetable, so anyone holding those faces the same dates.
The Bottom Line
FMED is a reminder that a good year does not save a small fund. The fund gained 21.4% over the past year and 21.0% in 2026, turning $10,000 invested a year ago into $12,136. But over five years it returned almost nothing, its assets had shrunk to about $50 million, and investors had pulled $36.79 million out over the past year. Fidelity is closing it, along with four other thematic funds, and the liquidation is expected on or about 19 November 2026. Shareholders who held on get cash, not shares, and the lesson for the next thematic fund is to check the size, the cost and the longer record before the good year, not after it. This article is not financial advice, and anyone holding FMED should check the liquidation notice from Fidelity and their broker before acting.
Figures in this article come from the sources linked in the text: Fidelity’s announcement of 15 October 2026, published on Fidelity’s newsroom and Nasdaq, for the liquidation dates and the five funds; StockTitan’s FMED return calculator, through 12 November 2026, for the 1-year return, the $10,000 figures and the year-by-year returns; Fidelity’s annual shareholder report as of 31 May 2026 for the 1-year, 5-year and life-of-fund returns and the $10,000 since-launch figure; the American Association of Individual Investors, data as of 31 October 2026, for net asset value returns, annual returns, assets and category averages; PortfoliosLab, 13 to 17 November 2026, for recent returns, the XLV comparison and drawdowns; StockAnalysis, at the 12 November 2026 close, for the final price, holdings and dividend history; ETF Database for fund flows, the expense ratio and valuation; and MarketBeat for trading volume.
Frequently Asked Questions
When did FMED stop trading?
12 November 2026 was the last full trading day for FMED on Nasdaq. Shares could be sold until the market close that day, and they no longer trade after it.
When does FMED liquidate?
The fund is expected to liquidate on or about 19 November 2026, according to Fidelity’s announcement of 15 October 2026. Shareholders should then receive cash liquidation proceeds through their broker.
What is $10,000 invested in FMED a year ago worth now?
$12,136, according to StockTitan’s calculator, based on the closing price of $32.74 on 12 November 2026. The fund returned 21.4% over the past year, and the figure is the same with dividends reinvested because FMED paid no dividend in 2025 or 2026.
Why is Fidelity closing FMED?
Fidelity did not give a reason in its announcement. The fund was small, with about $52 million in assets at the end of October 2026, and it had seen $36.79 million of net outflows over the past year. Its 5-year average annual return was minus 2.35%.
What happens if I still hold FMED shares?
You cannot sell them on an exchange. The fund is converting its portfolio to cash and is expected to liquidate on or about 19 November 2026, after which shareholders should receive the cash proceeds based on the final net asset value. Check the corporate-action notice from your broker for the exact amount and timing.
Can I still buy FMED?
No. Trading ended on 12 November 2026, and Fidelity is liquidating the fund. The same timetable applies to the other four funds in the announcement: FDFF, FDIF, FMET and FPRO.
About the Author

Chris Tzitzis
Chris Tzitzis has spent 10+ years explaining personal finance, taxes, investing, and crypto in plain language. Chris turns fine print into clear, verifiable steps, covering IRS relief programs, retirement contribution rules, and life and car insurance, so readers can check eligibility, limits, and costs for themselves. Chris’s guides focus on what is actually true, what applies, and where to verify it, rather than on promises or shortcuts.













